

**Indivior PLC Files 2024 Annual Report on Form 10-K**

**Richmond, VA, March 4, 2025** - Indivior PLC (NASDAQ/LSE: INDV) filed its Annual Report on Form 10-K for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission ("SEC") on March 3, 2025. The Annual Report on Form 10-K is now available at [www.sec.gov](http://www.sec.gov) and under the "Investors" section of the Company's website ([www.indivior.com](http://www.indivior.com)).

**About Indivior**

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit [www.indivior.com](http://www.indivior.com) to learn more. Connect with Indivior on LinkedIn by visiting [www.linkedin.com/company/indivior](https://www.linkedin.com/company/indivior).

**Contact:**

Jason Thompson  
Vice President, Investor Relations  
Tel: 804-402-7123 or [jason.thompson@indivior.com](mailto:jason.thompson@indivior.com)

Tim Owens  
Director, Investor Relations  
Tel: 804-263-3978 or [timothy.owens@indivior.com](mailto:timothy.owens@indivior.com)

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPKNBQCBKDANK